Nicholas Investment Partners LP trimmed its holdings in shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 21.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,354 shares of the specialty pharmaceutical company’s stock after selling 4,621 shares during the quarter. Nicholas Investment Partners LP’s holdings in Jazz Pharmaceuticals were worth $2,337,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. AXA increased its holdings in Jazz Pharmaceuticals by 23.2% during the third quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock valued at $17,091,000 after buying an additional 22,007 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Jazz Pharmaceuticals in the third quarter worth $296,000. Boston Partners purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $161,470,000. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 20.1% in the fourth quarter. LSV Asset Management now owns 159,570 shares of the specialty pharmaceutical company’s stock worth $21,486,000 after purchasing an additional 26,740 shares during the last quarter. Finally, Schroder Investment Management Group purchased a new position in Jazz Pharmaceuticals in the third quarter worth $52,571,000. 90.25% of the stock is currently owned by institutional investors.
Several research firms have issued reports on JAZZ. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $201.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, March 1st. BMO Capital Markets lifted their price target on shares of Jazz Pharmaceuticals from $196.00 to $199.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $164.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, February 20th. B. Riley reaffirmed a “buy” rating and issued a $206.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, January 16th. Finally, Deutsche Bank set a $170.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $180.19.
Shares of Jazz Pharmaceuticals plc – (JAZZ) opened at $152.43 on Friday. Jazz Pharmaceuticals plc – has a one year low of $128.58 and a one year high of $163.75. The company has a current ratio of 3.29, a quick ratio of 3.15 and a debt-to-equity ratio of 0.57. The company has a market cap of $8,830.57, a price-to-earnings ratio of 17.09, a PEG ratio of 0.77 and a beta of 0.97.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc – (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.